Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Vivani Medical, Inc.

Ticker
VANI
Sector
Industry
Report date
November 15, 2026
Valye AI Score

96

Very high visibility
Recent developments
Recent developments summary

Recent developments include positive Phase 1 results for the semaglutide implant NPM-139, a mild widening of Q3 2026 losses to $7 million, ongoing clinical trial progress, and collaborations with Novo Nordisk. The company secured funding for GLP-1 implant trials and announced plans for a spin-off of its Cortigent subsidiary.

Recent developments:
  • Vivani Medical reported positive Phase 1 clinical trial results for its semaglutide implant NPM-139, though the stock declined following the announcement [N2].
  • The company's Q3 2026 net loss widened mildly to $7 million, with data for the GLP-1 implant expected later in the week [N3].
  • Vivani entered a deal with Novo Nordisk to evaluate the semaglutide drug implant NPM-139 and eyed an August human trial following this collaboration [N4][N5].
  • The company secured funding for the GLP-1 implant trial in early 2026 [N6].
  • Vivani's subsidiary Cortigent presented advanced brain-implant technology at NANS 2026 and is planned for spin-off as an independent Nasdaq company [N7].
  • Anthony Baldor was appointed CFO in June 2025, succeeding Brigid Makes [N8].
  • Recent industry news includes FDA approvals for other companies and sector-wide developments impacting biopharmaceuticals [N1].
Overview

Vivani Medical, Inc. focuses on developing proprietary NanoPortal implant technology to deliver medicines via miniaturized, subdermal drug implants targeting chronic diseases with high unmet medical need. Its product candidates include NPM-139 and NPM-133 (semaglutide implants) and OKV-119 (exenatide implant for companion animals). The company completed a business combination in 2022 and has no approved products or commercial revenues. Vivani's operations have incurred consistent losses, reflecting ongoing research and development and clinical trial activities. The company has partnered with Novo Nordisk to evaluate the semaglutide implant and secured funding for clinical trials. Vivani also plans to spin off its Cortigent subsidiary, which develops brain-implant technology.

Executive summary

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company developing proprietary NanoPortal technology and miniaturized drug implants for chronic diseases. The company has no approved products and has incurred consistent operating losses, reporting a net loss of $7.25 million for Q3 2026 and holding $14.59 million in cash as of September 30, 2026. Vivani's pipeline includes semaglutide and exenatide implants, with recent positive Phase 1 results for the semaglutide implant NPM-139 and a collaboration with Novo Nordisk. The company faces typical clinical-stage risks including the need for additional capital, regulatory approval uncertainties, and commercialization challenges. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for VANI

Bull case model:

Vivani Medical's proprietary NanoPortal technology and its pipeline of drug implants, including the semaglutide implant NPM-139, represent innovative approaches to chronic disease treatment. Positive Phase 1 clinical results and collaboration with Novo Nordisk to evaluate the semaglutide implant support the potential for advancing clinical development. The planned spin-off of Cortigent could unlock value by focusing on brain-implant technology. Successful clinical milestones and regulatory approvals could enable Vivani to establish a novel drug delivery platform with commercial potential.

Bear case model:

Vivani Medical faces significant risks typical of clinical-stage biopharmaceutical companies, including the absence of approved products, ongoing operating losses, and the need for substantial additional financing. Clinical development is uncertain and costly, with no assurance of regulatory approval or commercial success. The company must also manage the transition to commercial operations if approvals are obtained. Failure to secure adequate funding or to demonstrate safety and efficacy could materially impair Vivani's business and financial condition.

Moat:

Vivani Medical's moat centers on its proprietary NanoPortal technology enabling miniaturized, subdermal drug implants for long-term delivery of medicines. This platform technology, combined with partnerships such as with Novo Nordisk and Okava, and its pipeline of implant candidates targeting chronic diseases, provides a differentiated approach in drug delivery. However, as a clinical-stage company with no approved products, the moat is contingent on successful clinical development, regulatory approvals, and eventual commercialization.

Risks overview
Risks summary
The biggest risk for Vivani Medical is the uncertainty inherent in clinical development and regulatory approval processes combined with the need for substantial additional financing to sustain operations and advance its product candidates.
Risks details:

• Clinical and Regulatory Risk: Vivani's product candidates require successful completion of clinical trials and regulatory approvals, which are uncertain and may result in delays or failure to obtain marketing authorization.
• Financial Risk: The company has incurred consistent losses and requires substantial additional capital to continue operations and clinical development. Failure to secure funding could force delays or reductions in business activities.
• Commercialization Risk: Even if regulatory approval is obtained, Vivani must establish manufacturing, marketing, and sales capabilities or partnerships, and achieve market acceptance, which pose significant challenges.
• Operational Risk: Vivani must attract and retain qualified personnel and manage collaborations effectively to advance its product pipeline and business objectives.

FINAL FORECAST FOR VANI

Final take one line
Vivani Medical is a clinical-stage biopharmaceutical company with high visibility into its implant technology development, clinical progress, and financial position, facing typical risks of clinical-stage firms.
Final take 12 to 24 month view

Business trends: Continued clinical development of proprietary NanoPortal implant technology and drug candidates, including semaglutide implants, with collaborations and funding secured.
Execution milestones: Completion of clinical trials phases, regulatory submissions, and potential commercialization preparations; spin-off of Cortigent subsidiary.
Key risks: Clinical and regulatory uncertainties, need for substantial additional capital, commercialization challenges, and operational execution risks.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

96
LLM visibility overview
LLM Visibility known facts
  • Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary NanoPortal technology and miniaturized, subdermal drug implant candidates for long-term delivery of medicines targeting chronic diseases with high unmet medical need.
  • The company's product pipeline includes NPM-139 (semaglutide implant), NPM-133 (semaglutide implant), and OKV-119 (exenatide implant for companion animals).
  • Vivani has partnered with Okava for the development of OKV-119, targeting cardiometabolic disorders in dogs and cats.
  • None of Vivani's drug candidates have received marketing approval or are commercially available.
  • The company completed a business combination in August 2022 forming its current structure.
  • Vivani reported net losses of $20.4 million for the nine months ended September 30, 2026, and $26.6 million for the year ended December 31, 2025, with an accumulated deficit of $168.9 million as of September 30, 2026.
  • As of September 30, 2026, Vivani had $14.59 million in cash and cash equivalents, current assets of $15.83 million, current liabilities of $6.59 million, a current ratio of 2.4, and a cash ratio of 2.22.
  • The company has not generated revenue from product sales and does not anticipate doing so in the foreseeable future.
  • Vivani's ability to generate revenue and achieve profitability depends on successful completion of clinical trials, regulatory approvals, manufacturing scale-up, commercial launch, and market acceptance of its product candidates.
  • Vivani has ongoing clinical trials including a Phase 1 trial for the semaglutide implant NPM-139, with positive Phase 1 results recently reported.
  • Vivani entered a deal with Novo Nordisk to evaluate the semaglutide drug implant NPM-139 and eyed an August human trial following this collaboration.
  • The company secured funding for the GLP-1 implant trial in early 2026.
  • Vivani announced plans to spin off its subsidiary Cortigent, which develops advanced brain-implant technology, as an independent Nasdaq-listed company in 2025.
  • Anthony Baldor was appointed CFO in June 2025, succeeding Brigid Makes.
  • Recent news highlights include Vivani's Q3 2026 loss widening mildly to $7 million and anticipation of data for the GLP-1 implant.
  • The company reported successful initial data from the LIBERATE-1™ study and secured $3 million in equity financing in 2025.
  • Vivani's CEO presented on innovative drug delivery solutions at an AAPS virtual workshop in 2025.
  • The company faces risks typical of clinical-stage biopharmaceutical firms, including the need for substantial additional financing, regulatory approval uncertainties, and the challenge of transitioning to commercial operations if approvals are obtained.
Sources
Sources - Context summary

Generated 2026-11-15

Sources - Earning calls
Sources - Other context
  • Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Sources - SEC Filings
  • S1 | 2026-03-26 | 10-K
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals | https://www.nasdaq.com/articles/weekly-buzz-lly-jnj-win-fda-nod-sion-nnox-cut-jobs-pfe-argx-strike-deals
  • N2 | 2026-11-12 | www.nasdaq.com | Vivani Medical Reports Positive Phase 1 Results For Semaglutide Implant NPM-139; Stock Down | https://www.nasdaq.com/articles/vivani-medical-reports-positive-phase-1-results-semaglutide-implant-npm-139-stock-down
  • N3 | 2026-11-12 | www.nasdaq.com | Vivani's Q3 Loss Widens Mildly To $7 Mln; Data For GLP-1 Implant Expected Later This Week | https://www.nasdaq.com/articles/vivanis-q3-loss-widens-mildly-7-mln-data-glp-1-implant-expected-later-week
  • N4 | 2026-07-15 | www.nasdaq.com | Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal | https://www.nasdaq.com/articles/vivani-medical-eyes-august-human-trial-semaglutide-implant-after-novo-nordisk-deal
  • N5 | 2026-07-07 | www.nasdaq.com | Vivani Medical In Deal With Novo Nordisk To Evaluate Semaglutide Drug Implant NPM-139 | https://www.nasdaq.com/articles/vivani-medical-deal-novo-nordisk-evaluate-semaglutide-drug-implant-npm-139
  • N6 | 2026-03-30 | www.nasdaq.com | Vivani Medical Secures Funding for GLP-1 Implant Trial | https://www.nasdaq.com/articles/vivani-medical-secures-funding-glp-1-implant-trial
  • N7 | 2026-01-23 | www.nasdaq.com | Vivani Subsidiary Cortigent To Present Advanced Orion Brain-Implant Technology At NANS 2026, Today | https://www.nasdaq.com/articles/vivani-subsidiary-cortigent-present-advanced-orion-brain-implant-technology-nans-2026
  • N8 | 2025-06-11 | www.nasdaq.com | Vivani Medical Appoints Anthony Baldor To Succeed Brigid Makes As CFO | https://www.nasdaq.com/articles/vivani-medical-appoints-anthony-baldor-succeed-brigid-makes-cfo
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine